Maria Pineda

Maria Luisa Pineda, PhD, is the Co-founder and CEO of Envisagenics. Dr. Pineda has over a decade of experience as a researcher and, before starting Envisagenics, she was a life science venture capital investor. Under her leadership, Envisagenics has received non-dilutive SBIR grants from the National Institutes of Health, generated significant revenue from biopharma, raised capital from investors like Microsoft’s VC arm (M12), and won several prestigious artificial intelligence competitions, including the JLABS Artificial Intelligence for Drug Discovery QuickFire Challenge. Last year, Dr. Pineda secured an oncology collaboration with the Lung Cancer Initiative at Johnson & Johnson, and she looks forward to closing more commercial partnerships to accelerate drug development leveraging SpliceCore®, Envisagenics’ AI platform that develops novel therapeutics for RNA splicing variants.